Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01494285 |
Recruitment Status
:
Completed
First Posted
: December 16, 2011
Last Update Posted
: December 3, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acne Vulgaris | Drug: ARK-E021 5% Drug: ARK-E021 10% Drug: Placebo | Phase 1 Phase 2 |
This is a phase I/II prospective, multicenter, randomized, double blind, placebo controlled, parallel group, dose range finding clinical study to evaluate the safety, tolerability and preliminary efficacy of ARK-E021 foam for treatment of acne vulgaris.
It is anticipated that the study will be conducted at the listed Medical Centers as well as out-patient clinics at the community.
Approximately 144 male and female subjects with mild to moderate facial acne vulgaris will be enrolled in this study. Following satisfaction of the entry criteria and screening procedures, subjects will be randomized to either 5% or 10% topical foam (ARK-E021) or placebo foam. Subjects will apply the study medication once daily on the face at bedtime for 12 weeks followed by a post-treatment follow up visit 4 weeks after end of treatment. The first dose will be applied in the presence of the study investigator or his assignee. Subsequent applications will be made by the patient.
Safety will be monitored throughout the study duration. Efficacy will be assessed by facial lesion counts and by the investigator global evaluation of acne severity at baseline and at weeks 3, 6, 9, 12 and 16.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 157 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, Ambulatory Safety and Efficacy Study of ARK-E021 Topical Foam of 5% and 10% in Subjects With Mild to Moderate Acne Vulgaris. |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | October 2013 |
Actual Study Completion Date : | October 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: ARK-E021 5% foam |
Drug: ARK-E021 5%
Topically applied once daily at bedtime
Other Name: Not yet marketed
|
Experimental: ARK-E021 10% foam |
Drug: ARK-E021 10%
Topically applied once daily at bedtime
Other Name: Not yet marketed
|
Placebo Comparator: Placebo foam |
Drug: Placebo
Topically applied once daily at bedtime
Other Name: Not marketed
|
- To evaluate the safety and tolerability of ARK-E021 topical foam in subjects with acne vulgaris. [ Time Frame: Baseline through week 16. ]
Subject safety will be assessed following treatment using measurements of the following variables:
- Physical examination.
- Vital Signs (HR, BP, Body temperature).
- Adverse events recording.
- Concomitant medications.
- To evaluate the efficacy of ARK-E021 topical foam in subjects with acne vulgaris. [ Time Frame: Baseline through week 16. ]
Subject efficacy will be assessed following treatment using measurements of the following variables:
- Lesion count (inflammatory/non inflammatory and total).
- Investigator global assessment (IGA; grade 0-4).
- Lesion documentation by photographs (optional).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 40 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Patient is male or female between the ages of 12 to 40.
- A clinical diagnosis of acne vulgaris with facial involvement.
- Minimum of 15 inflammatory lesions on the face (papules and/ or pustules)but not more than 40.
- Existence of non-inflammatory lesions on the face (opened and/or closed comedones).
- A score of ≥2 (moderate) on the investigator's global assessment scale.
- Use of non oral contraceptives in female of childbearing potential during the study.
- No known medical conditions that, in the Investigator's opinion could interfere with study participation.
- Patient is willing and able to comply with all the requirement of the study protocol.
- Patient is willing and able to give written informed consent prior to participation in the study.
Main Exclusion Criteria:
- Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne), or severe acne requiring systemic treatment.
- One or more active nodule/cyst acne on the face (inactive lesions allowed).
- Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
- Participation in another investigational drug trial within 30 days prior to study entry.
-
Concomitant medication:
- Use of systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris, systemic anti-inflammatory agents within 4 weeks prior to baseline or during the study.
- Use of topical steroids, topical antibiotics, topical treatment for acne vulgaris, topical anti-inflammatory agents within 2 weeks prior to baseline or during the study.
- Treatment for acne with isotretinoin or isotretinoin derivatives within 12 months prior to study entry.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01494285
Israel | |
HaEmek Medical Center | |
Afula, Israel | |
Meir Medical Center | |
Kfar Saba, Israel | |
Souraski Medical Center | |
Tel Aviv, Israel |
Responsible Party: | M. Arkin 1999 Ltd. |
ClinicalTrials.gov Identifier: | NCT01494285 History of Changes |
Other Study ID Numbers: |
MA1001 |
First Posted: | December 16, 2011 Key Record Dates |
Last Update Posted: | December 3, 2013 |
Last Verified: | December 2013 |
Keywords provided by M. Arkin 1999 Ltd.:
Acne Vulgaris Topical Foam |
Additional relevant MeSH terms:
Acne Vulgaris Acneiform Eruptions Skin Diseases Sebaceous Gland Diseases |